{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:34:09Z","timestamp":1793205249715,"version":"4.5.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1681\/asn.2009060593","type":"journal-article","created":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T21:42:10Z","timestamp":1266529330000},"page":"527-535","source":"Crossref","is-referenced-by-count":450,"title":["Avosentan for Overt Diabetic Nephropathy"],"prefix":"10.1681","volume":"21","author":[{"given":"Johannes F.E.","family":"Mann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Jamerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Kuranoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Littke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Viberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-23-20230410","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1172\/JCI27699","article-title":"Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes","volume":"116","author":"Remuzzi","year":"2006","journal-title":"J Clin Invest"},{"key":"R2-23-20230410","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R3-23-20230410","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"R4-23-20230410","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"R5-23-20230410","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000045906","article-title":"Effects of endothelin receptor antagonists on the progression of diabetic nephropathy","volume":"87","author":"Hocher","year":"2001","journal-title":"Nephron"},{"key":"R6-23-20230410","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/ncpneph0891","article-title":"Reversal of proteinuric renal disease and the emerging role of endothelin","volume":"4","author":"Barton","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"R7-23-20230410","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5414\/CPP43178","article-title":"Multiple-dose pharmacokinetics, pharmacodynamics and tolerability of the oral ET(A) endothelin-receptor antagonist SPP301 in man","volume":"43","author":"Dieterle","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R8-23-20230410","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11906-999-0077-7","article-title":"Endothelin in cardiovascular control: The role of endothelin antagonists","volume":"1","author":"Wenzel","year":"1999","journal-title":"Curr Hypertens Rep"},{"key":"R9-23-20230410","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"The endothelin antagonist avosentan reduces albumin excretion rate in diabetic patients with macroalbuminuria: A randomized, placebo-controlled, double-blind trial","volume":"20","author":"Wenzel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R10-23-20230410","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"R11-23-20230410","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/archinte.165.8.947","article-title":"The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: Results of the African American Study of Kidney Disease and Hypertension","volume":"165","author":"Lea","year":"2005","journal-title":"Arch Intern Med"},{"key":"R12-23-20230410","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1161\/01.CIR.0000118499.69469.51","article-title":"Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: A comparison of selective and combined endothelin receptor blockade","volume":"109","author":"Goddard","year":"2004","journal-title":"Circulation"},{"key":"R13-23-20230410","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1097\/01.ASN.0000141313.84470.4B","article-title":"Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism","volume":"15","author":"Goddard","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R14-23-20230410","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.amjhyper.2005.06.008","article-title":"Effect of BQ-123, an endothelin antagonist, on renal hemodynamics, tubular function, vasoactive hormones, and blood pressure in healthy humans: A dose response study","volume":"18","author":"Pedersen","year":"2005","journal-title":"Am J Hypertens"},{"key":"R15-23-20230410","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.ajkd.2006.10.014","article-title":"Antihypertensive therapy in the presence of proteinuria","volume":"49","author":"Sarafidis","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"R16-23-20230410","first-page":"39","article-title":"Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An updated meta-analysis","volume":"10","author":"Weidmann","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"R17-23-20230410","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1345\/aph.1L024","article-title":"Efficacy and safety of darusentan: A novel endothelin receptor antagonist","volume":"42","author":"Epstein","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R18-23-20230410","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2165\/00003495-200464100-00001","article-title":"Endothelin receptor antagonists in heart failure: Current status and future directions","volume":"64","author":"Ertl","year":"2004","journal-title":"Drugs"},{"key":"R19-23-20230410","first-page":"696","article-title":"Clinical trials of endothelin antagonists in heart failure: A question of dose?","volume":"231","author":"Kelland","year":"2006","journal-title":"Exp Biol Med (Maywood"},{"key":"R20-23-20230410","first-page":"371","article-title":"Do endothelin receptor antagonists induce edema through extravasation of fluids?","volume":"26","author":"Maillard","year":"2009","journal-title":"J Hypertens"},{"key":"R21-23-20230410","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/clpt.2009.15","article-title":"Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects","volume":"85","author":"Smolander","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R22-23-20230410","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function: Measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N Engl J Med"},{"key":"R23-23-20230410","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values","volume":"53","author":"Levey","year":"2007","journal-title":"Clin Chem"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201003000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:32:14Z","timestamp":1786131134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201003000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2009060593","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}